key: cord-1028156-qns8jsj1 authors: Pandey, Ritambhara; Rai, Devesh; Tahir, Muhammad Waqas; Wahab, Abdul; Bandyopadhyay, Dhrubajyoti; Lesho, Emil; Laguio-Vila, Maryrose; Fentanes, Emilio; Tariq, Raseen; Naidu, Srihari S.; Aronow, Wilbert S. title: Prevalence of comorbidities and symptoms stratified by severity of illness amongst adult patients with COVID-19: a systematic review date: 2022-03-28 journal: Arch Med Sci Atheroscler Dis DOI: 10.5114/amsad.2022.115008 sha: b3d8a6aad89912ff42855fe735b2612ea41f7139 doc_id: 1028156 cord_uid: qns8jsj1 INTRODUCTION: We performed a systematic review of comorbidities and symptoms of adult patients with coronavirus disease 2019 (COVID-19) to evaluate comorbidities, symptoms, and severity. MATERIAL AND METHODS: We searched databases and extracted comorbidities and symptoms from the included studies. We stratified the similar signs and symptoms in groups and on the basis of severity and compared them with stratified analysis. Individual case reports and case series with < 5 patients were excluded. RESULTS: A total of 163 studies with 43,187 patients were included. Mean age was 54.6 years. There were significantly fewer women in the study (43.9% vs. 56.1%, p < 0.0001). Prevalent cardiovascular comorbidities were hypertension (31.9%), obesity (27.9%), hyperlipidemia (26.4%), smoking (18.9%), diabetes mellitus (17.2%), atherosclerotic disease (9.2%) and arrhythmia (5.0%). The most frequently reported constitutional symptoms of COVID-19 were fever (73.9%), fatigue (33.4%), malaise (29.9%), myalgia and/or arthralgia (19.2%), generalized weakness (19.0%), and chills (11.3%). For the cardiovascular system, chest pain and/or tightness were most often reported (19.6%), followed by palpitations (5.2%). Hypertension and diabetes were common in severe disease. Obesity and congestive heart failure were not observed in any non-severe cases. Severe cases compared to non-severe cases more frequently had fever (87.8% vs. 58.5%, p < 0.001), shortness of breath (47.4% vs. 20.6%, p < 0.001), cough (66.8% vs. 62.9%, p < 0.001), sputum production (35.4% vs. 26.5%, p < 0.001) and rhinorrhea (32.2% vs. 7.3%, p < 0.001). CONCLUSIONS: Hypertension, diabetes, and atherosclerotic diseases are common comorbidities across the world, with obesity as the second most common in the US and more common in men. Coronavirus disease 2019 (COVID- 19) is now a global pandemic caused by a novel coronavirus. The first case of COVID-19 was reported in December 2019 in Wuhan, China. Since then, it has affected over 138,010,168 people and caused over 2,970,000 deaths across the world [1] . Similar to other coronaviruses, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) primarily affects the pulmonary system. However, multi-system involvement, including cardiac, vascular, and neurological complications, has been reported [2] . The clinical manifestations range from asymptomatic infection or mild disease with fever, myalgias, and cough to severe disease characterized by shortness of breath, hypoxemia, acute respiratory distress syndrome requiring mechanical ventilation, multi-organ failure, and death [3] . However, due to this disease's novelty, within the first year of the initial description, the prevalence of various symptoms and comorbidities associated with the disease remains unclear. Several studies have evaluated the prevalence of various symptoms. A systematic review of 3600 patients reported fever, cough, and fatigue as most common [4] . Similarly, another meta-analysis of 78 studies found the prevalence of gastrointestinal symptoms to be 1 out of every 5 COVID-19 patients [5] . Another systematic review described the prevalence of acute myocardial injury in COVID-19 infection and found a pooled prevalence of nearly 20% [6] . Given the variable presentations and unclear prevalence of comorbidities and the accrual of interim experience, we performed a systematic review to assess the contemporary prevalence of comorbidities and symptoms from all the published studies. We performed a systematic review following the Cochrane Handbook for Systematic Reviews and Intervention statement in health care interventions [7] . We included observational studies, case series (retrospective, prospective, descriptive), randomized controlled trials, and survey studies that included adults' comorbidities or symptoms with confirmed COVID-19 infection. Individual case reports and case series with < 5 patients were excluded. ; or Coronavirinae19 or Coronaviri-nae2019 or coronavirus19 or coronavirus2019 or COVID19 or COVID2019 or nCOV19 or nCOV2019 or;2019-nCOV or 2019nCOV or SARS Corona virus or SARS Coronavirus or SARS-COV-2. Two investigators (D.R. and R.P.) reviewed the titles and abstracts of the identified studies independently and screened them as per the selection criteria mentioned above. Any conflict was resolved with the consensus of a third investigator (R.T.). Data from included studies were independently abstracted by two investigators (D.R. and M.W.T.). The abstracted data included study design and setting, month and year of publication, duration of the study period, gender, comorbidities, symptoms and severity, mortality, survival, and discharge data. Data extraction excluded studies with pediatric patients. All comorbidities were initially abstracted separately, then grouped based on system involvement for data analysis. Similarly, all symptoms were extracted separately, then subsequently grouped for analysis. The frequency of variable occurrence was calculated using percentages. For comorbidity analysis, studies with fewer than 3 reported comorbidities were excluded. Primary analysis involved the calculation of the presence of comorbidities and symptoms in the pooled data. Comorbidities and symptoms were compared based on the severity of the patients studied. For this stratification, we included studies reporting symptoms or comorbidities exclusively for severe or non-severe cases. Studies with severe and non-severe cases with inseparable comorbidity or severity data were excluded. A c 2 test was performed with α set at 0.05. All analyses were performed using SPSS version 25. The preliminary database search resulted in 4032 studies; 24 other studies were identified from other sources; after the titles' preliminary screening, 233 full-text studies were reviewed. Of these, 163 studies were included in the systematic reviews and in the primary analysis of symptoms . For comorbidity analysis, 41 of 163 studies were excluded based on fewer than three reported comorbidities criteria, as described above, yielding 122 studies. A flow chart of the study selection is shown in Figure 1 . The details of the included studies are provided in Table I . A total of 163 studies with 43,187 patients were included. Of these, 117 were from China, 19 from the European region, 14 from the US, 2 from other countries, and the remaining 11 were from Australia, Brazil, Iran, Japan, S Korea, Singapore, and Taiwan. The earliest study recruitment started on December 11, 2019 and ended on April 19, 2020. There were 80 retrospective single-center case series; 43 retrospective multicenter case series, 7 retrospective multicenter cohorts, 3 retrospective single-center cohorts, 6 prospective single-center series, 3 prospective single-center series, 4 prospective single-center cohort studies, 1 prospective multicenter cohort study, 7 randomized controlled trials of various design, 1 open-label non-randomized control study, 1 descriptive case series, and 1 prospective single-center open-label study (Table I) . A total of 128 studies included only hospitalized patients, 13 included both hospitalized and non-hospitalized patients, 2 included only non-hospitalized patients, and 20 studies did not list hospitalization status. For a total of 40,632 patients, the mean age was 54.6 years, with a range of 18-98 years. A total of 8 studies, including adult patients with 2,325 patients, did not provide age data. Data regarding gender were not available in 8 studies. There were significantly fewer women in the study (43.9% vs. 56.1%, p < 0.0001). Hospitalization outcomes were reported in 116 studies for 37,349 patients; 48.5% (28, 779) were discharged, 29% (18,810) remained in the hospital, and 12.1% (4284) died at the end of the study period for these studies. The details regarding invasive mechanical ventilation (IMV) were reported in 61 studies with 30,190 patients, of whom 9.89% (3,359) underwent IMV. Prevalent cardiovascular comorbidities were hypertension (31.9%), obesity (27.9%), hyperlipidemia (26.4%), smoking (18.9%), diabetes mellitus (17.2%), atherosclerotic disease (9.2%) and arrhythmia (5.0%). Asthma (7.8%), followed by chronic obstructive lung disease (COPD) or chronic lung disease (CLD) (6.2%), were the most common respiratory comorbidities. The gastrointestinal comorbidities of hepatitis, liver disease and fatty liver disease had a prevalence of 2.4%. Chronic kidney disease and/or end-stage renal disease were reported in 6.2% of patients. Cerebrovascular disease or cerebrovascular accidents were reported in 3.5% of patients. Cancer and/or malignancy were reported in 4.4%, and HIV and/or immunodeficiency were observed in 1.6% of patients. The most often reported constitutional symptoms of COVID-19 were fever (73.9%), fatigue (33.4%), malaise (29.9%), myalgia and/or arthralgia (19.2%), generalized weakness (19.0%), and chills (11.3%). For the cardiovascular system, chest pain and/or tightness were most often reported (19.6%), followed by palpitations (5.2%). Cough (60.3%), sputum production (29.7%), shortness of breath (27.3%), loss of smell and/or taste (25.1%), rhinorrhea (12.9%), and sore throat (12.3%) were the most often reported respiratory symptoms. The most common gastrointestinal symptoms were anorexia or loss of appetite (29.4%), followed by diarrhea (14.8%), nausea and/or vomiting (13.2%), and abdominal pain (7.4%). Commonly reported neurological symptoms were headache (12.8%), confusion (9.4%), and dizziness (8.2%). The details of the prevalence of constitutional, cardiovascular, respiratory, and gastrointestinal symptoms, and their related comorbidities, along with the number of studies, are shown in Tables II and III, respectively. For stratification based on severity for comorbidities and symptoms, only 30 studies met the inclusion criteria, with a total of 5,819 cases. Table IV shows the prevalence of comorbidities and symptoms in both groups. Hypertension was the most commonly observed comorbidity among severe cases (45.2% vs. 8.1%, p < 0.001). Diabetes mellitus was also more common in severe disease (19.5% vs. 3.5%, p < 0.001). Obesity and congestive heart failure (CHF) were not observed in any non-severe cases among the studies included for this analysis but were present in severe cases (30.5% and 5.2%, respectively). Smoking was more commonly observed in non-severe cases than severe cases (13.5% vs. 3.8%, p < 0.001). COPD was similar in non-severe and severe cases (9.2% vs. 12.0%, p = 0.083). Among all the symptoms compared, non-respiratory symptoms were more commonly observed among non-severe cases (headaches, anorexia, abdominal pain, loss of smell/taste). Severe compared to non-severe cases more frequently had fever (87.8% vs. 58.5%, p < 0.001), shortness of breath (47.4% vs. 20.6%, p < 0.001), cough (66.8% vs. 62.9%, p < 0.001), sputum production (35.4% vs. 26.5%, p < 0.001) and rhinorrhea (32.2% vs. 7.3%, p < 0.001). Both groups had a similar prevalence of chest pain (21.1% severe vs. 19.3% non-severe, p = 0.34), diarrhea (20.2% severe vs. 19 .4% non-severe, p = 0.515), and nausea/vomiting (8.8% severe vs. 8.4% non-severe, p = 0.643). Since the emergence of SARS-CoV-2 infection in China and its spread worldwide, the knowledge regarding disease course, clinical characteristics, and treatment options has continued to evolve. We performed a comprehensive systematic review of published studies with COVID-19 patients. This systematic review summarized the prevalence of clinical symptoms and comorbidities in COVID-19 patients, stratified by the severity of symptoms [164] [165] [166] [167] [168] [169] [170] . This analysis found that the prevalence of COVID-19 was higher in men compared to women. Hypertension, obesity, hyperlipidemia, smoking, diabetes mellitus, and atherosclerotic diseases are the most common comorbidities overall. Fever, cough, fatigue, malaise, sputum production, shortness of breath, and anosmia are the most common symptoms overall. After stratification of patients on the basis of severity, hypertension, diabetes, obesity, and CHF were the most common comorbidities in severe illness. In contrast, smoking is more common in non-severe illnesses. Fever, shortness of breath, cough, sputum production, and rhinorrhea are more commonly reported in patients with severe illness, whereas headache, anorexia, abdominal pain, and loss of smell/taste are reported more often in patients with non-severe illness. We report a higher prevalence of COVID-19 in men compared to women. An analysis of 14,712 patients revealed men to have significantly higher mortality than women even after adjusting for comorbidities [171] . Gender differences have been reported in the prior influenza pandemic, suggesting that men are more susceptible to viral respiratory illness; this is attributed to females generating stronger innate and adaptive immune responses [172, 173] . Thus, it could be why SARS-CoV-2, being a respiratory virus, was noted to have a higher prevalence in men in our study. One study evaluating 524 SARS-CoV-2 patients ages 51 to 70 found that males were significantly more likely to be hospitalized and had increased mortality regardless of age [174] . It could be hypothesized that women have a robust immune response to viruses as seen with the influenza virus as well; hence that could be the reason for the protection of females against SARS-CoV 2 infection. We found the most common comorbidities to be hypertension and diabetes; these results are consistent with prior studies with a similar prevalence of hypertension and diabetes ranging from 13% to 27% and 7% to 12%, respectively [4, 175] . The slightly higher prevalence of hypertension and diabetes in this study could be attributed to the inclusion of studies worldwide. In contrast, prior studies included only studies from China. The prevalence of obesity was 27.9% from 9 studies; interestingly, all these studies were from the US. Obesity has also been postulated to be a risk factor for COVID-19 by the dysregulation of the immune system due to excess adiposity and decreased diaphragm contractility [176] . Smoking was more common in non-severe patients; the "smoker's paradox" has been proposed as a possible mechanism suggesting smoking to have a protective effect, although this hypothesis continues to remain controversial [177] . Hypertension, hyperlipidemia, smoking, diabetes mellitus, and obesity are well-known cardiovascular risk factors [178] . Heart disease, stroke, and diabetes are known risk factors for influenza and its complications. SARS-CoV-2, being a respiratory virus, could also be hypothesized to have a similar risk factor [179] . Several hypotheses have been proposed for the cardiovascular complications of SARS-CoV-2, including angiotensin-converting enzyme-2 mediated cardiac damage, direct viral injury to myocardium, and hypoxemia mediated damage. However, none of these hypotheses have been proven yet [6, 180, 181] . Our findings suggest a higher prevalence of cardiovascular comorbidities in severe cases, which could be likely because of myocardial injury in these patients. The presence of comorbidities, including hypertension, diabetes mellitus, and atherosclerotic disease, was noted to be significantly higher in the severely ill patient population, which is corroborated by prior studies [19, 24, 35, 182] . Our study is in concordance with a prior meta-analysis of 43 studies with 3600 patients reporting fever, cough, and fatigue to be the most common clinical symptoms, suggesting COVID-19 to have primary respiratory system involvement [4] . In our study, fever was the most common presenting symptom as well [4, 35, 54, 109] . Respiratory symptoms of shortness of breath, cough, sputum production, and rhinorrhea were more common in severe illnesses, whereas non-respiratory symptoms are more common in non-severe disease. This could be because dyspnea and the need for supplemental oxygen are the criteria for severe illness. Initial studies were suggestive of COVID-19 being primarily a respiratory illness; however, recent studies suggest COVID-19 to be a multi-system disorder with the involvement of cardiovascular, gastrointestinal, musculoskeletal, and nervous systems. We report the involvement of respiratory, cardiovascular, gastrointestinal, musculoskeletal, and nervous systems, suggesting that COVID-19 is a multi-system disease with primary respiratory system involvement. Our study reports a low prevalence (25.1% in 7952 from 13 studies) of loss of smell or taste; this is likely because of the inclusion of outpatient and survey studies in our review. A review focusing on olfactory dysfunction reported that up to 80% of patients with COVID-19 might develop subjective olfactory dysfunction in the disease's initial stages [183] . The lower prevalence in our study can be attributed to the inclusion of more inpatient studies in our analysis, as loss of smell tends to be an early-onset symptom and not recognized in inpatients. A review focusing on musculoskeletal symptoms of 12,046 patients reported occurrence of fatigue in 25.6% and arthralgia and/or myalgia in 15.5% of patients. Our study also showed a similar prevalence of these symptoms, although they seem to be nonspecific and represent viral prodromal symptoms for most of the respiratory viruses [184] . Our study's strength lies in its large patient population of more than 40,000 cases, including inpatients and outpatients, severe and non-severe cases, and spread over multiple continents. Our study has certain limitations as the majority of studies included in our study are observational. Even though our study included patients across the world, the majority of studies originate from China. Of concern, many of the studies were incomplete and did not include a comprehensive picture of the patients such as outcomes on discharge. Additionally, most of the studies were in inpatient settings, thus under-representing cases within the community. Lastly, the literature evolving around COVID-19 is very dynamic and rapidly evolving, especially in terms of outcomes. In conclusion, the prevalence of COVID-19 was found to be higher in men. Hypertension, diabetes, and atherosclerotic diseases are common comorbidities globally, and obesity is the second most common in the US. There is a higher prevalence of comorbid hypertension and diabetes amongst severely ill patients and a higher prevalence of fever, myalgia/arthralgia, shortness of breath, and cough symptoms in severely ill patients. We believe that further high-quality prospective studies are needed to identify the demographics and regional differences and ascertain characteristics of outpatient COVID-19 individuals. Extrapulmonary manifestations of COVID-19 Clinical management of COVID-19 Clinical characteristics of coronavirus disease 2019 (COVID-19) in China: a systematic review and meta-analysis Prevalence and mortality of COVID-19 patients with gastrointestinal symptoms: a systematic review and meta-analysis Acute myocardial injury in patients hospitalized with COVID-19 infection: a review Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement Acute myocardial injury at hospital admission is associated with all-cause mortality in COVID-19 Acute myocardial injury is common in patients with covid-19 and impairs their prognosis Adjuvant corticosteroid therapy for critically ill patients with COVID-19 Analysis of epidemiological and clinical features in older patients with coronavirus disease 2019 (COVID-19) outside Wuhan Analysis of imported cases of covid-19 in Taiwan: a nationwide study Association between initial chest CT or clinical features and clinical course in patients with coronavirus disease 2019 Pneumonia Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China Association of chemosensory dysfunction and Covid-19 in patients presenting with influenza-like symptoms Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York State C or r e sp ondence Clinical Characteristics of Covid-19 in China Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19) Characteristics and clinical significance of myocardial injury in patients with severe coronavirus disease 2019 Characteristics and early prognosis of covid-19 infection in fracture patients Characteristics of COVID-19 infection in Beijing Characteristics of patients with COVID-19 pneumonia at Hvidovre Hospital Chest CT findings in patients with coronavirus disease 2019 and its relationship with clinical features Clinical and autoimmune characteristics of severe and critical cases with COVID-19 Clinical and biochemical indexes from 2019-nCoV infected patients linked The clinical and chest CT features associated with severe and critical COVID-19 pneumonia Clinical and high-resolution CT Features of the COVID-19 infection: comparison of the initial and follow-up changes Clinical and laboratory findings from patients with COVID-19 pneumonia in Babol North of Iran: a retrospective cohort study Clinical and virologic characteristics of the first 12 patients with coronavirus disease 2019 (COVID-19) in the United States Clinical characteristics and imaging manifestations of the 2019 novel coronavirus disease (COVID-19): a multi-center study in Wenzhou city Clinical characteristics and outcomes of cancer patients with COVID-19 Clinical characteristics and outcomes of hospitalised patients with COVID-19 treated in Hubei (epicenter) and outside Hubei (non-epicenter): a nationwide analysis of China Clinical characteristics and outcomes of older patients with coronavirus disease 2019 (COVID-19) in Wuhan, China (2019): a single-centered, retrospective study Clinical characteristics and outcomes of patients undergoing surgeries during the incubation period of COVID-19 infection Clinical characteristics and outcomes of patients with severe covid-19 with diabetes Clinical characteristics and prognosis in cancer patients with COVID-19: a single center's retrospective study Clinical characteristics of 25 death cases infected with COVID-19 pneumonia: a retrospective review of medical records in a single medical center Clinical characteristics of 54 medical staff with COVID-19: a retrospective study in a single center in Wuhan Clinical characteristics of 80 hospitalized frontline medical workers infected with COVID-19 in Wuhan Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China Clinical characteristics of 145 patients with corona virus disease 2019 (COVID-19 Clinical characteristics of 161 cases of corona virus disease 2019 (COVID-19) in Changsha Clinical characteristics of 545 cases confirmed COVID-19 in Wuhan Stadium Cabin Hospital Clinical characteristics of and medical interventions for COVID-19 in hemodialysis patients in Wuhan Clinical characteristics of coronavirus disease 2019 in China Clinical characteristics of COVID-19 patients with digestive symptoms in Hubei, China: a descriptive, cross-sectional, multicenter study Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China The clinical characteristics of COVID-19: a retrospective analysis of 104 patients from the outbreak on board the Diamond Princess cruise ship in Japan Clinical characteristics of imported cases of COVID-19 in Jiangsu Province: a multicenter descriptive study Clinical characteristics of non-critically ill patients with novel coronavirus infection (COVID-19) in a Fangcang Hospital Clinical characteristics of non-ICU hospitalized patients with coronavirus disease 2019 and liver injury: a retrospective study Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province Clinical characteristics of patients with 2019 coronavirus disease in a non-Wuhan area of Hubei Province, China: a retrospective study Clinical characteristics of pregnant women with covid-19 in Wuhan, China Clinical characteristics of refractory COVID-19 pneumonia in Wuhan, China Clinical course and outcomes of 344 intensive care patients with COVID-19 Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine The clinical dynamics of 18 cases of COVID-19 outside of Wuhan, China Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data Clinical features and dynamics of viral load in imported and non-imported patients with COVID-19 Clinical features and outcomes of 98 patients hospitalized with sars-cov-2 infection in Daegu, South Korea: a brief descriptive study Clinical features and shortterm outcomes of 102 patients with corona virus disease 2019 in Wuhan, China 2. Institute of Radiation Medicine, China Academy of Medical Science & Peking Union Medical College Clinical features and shortterm outcomes of 221 patients with COVID-19 in Wuhan Clinical features and treatment of COVID-19 patients in northeast Chongqing Clinical features of 69 cases with coronavirus disease 2019 in Wuhan, China Clinical features of 85 fatal cases of COVID-19 from Wuhan. A retrospective observational study Clinical features of 2019 novel coronavirus pneumonia presented gastrointestinal symptoms but without fever onset Clinical features of coronavirus disease 2019 (COVID-19) in a cohort of patients with disability due to spinal cord injury Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China Clinical features of the first cases and a cluster of Coronavirus Disease 2019 (COVID-19) in Bolivia imported from Italy and Spain Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series Clinical hallmarks of 13 COVID-19 patients revealing SAA biomarker Clinical outcomes in 55 patients with severe acute respiratory syndrome coronavirus 2 who were asymptomatic at hospital admission in Shenzhen Clinical progression of patients with COVID-19 in Shanghai Clinicolaboratory study of 25 fatal cases of COVID-19 in Wuhan A comparative study on the clinical features of COVID-19 pneumonia to other pneumonias Coronavirus disease 19 infection does not result in acute kidney injury: an analysis of 116 hospitalized patients from Wuhan, China Coronavirus disease 2019 in elderly patients: characteristics and prognostic factors based on 4-week follow-up Corticosteroid treatment of patients with coronavirus disease 2019 (COVID-19) Covid-19 and kidney transplantation COVID-19 anosmia reporting tool: initial findings COVID-19 in a designated infectious diseases hospital outside Hubei Province, China COVID-19 in critically ill patients in the Seattle region -case series COVID-19 in solid organ transplant recipients: a single-center case series from Spain COVID-19 with different severities: a multicenter study of clinical features A cross-sectional comparison of epidemiological and clinical features of patients with coronavirus disease (COVID-19) in Wuhan and outside Wuhan, China CT characteristics of patients infected with 2019 novel coronavirus: association with clinical type CT features of coronavirus disease 2019 (COVID-19) pneumonia in 62 patients in Wuhan, China Diarrhea: an underestimated symptom in Coronavirus disease 2019 Digestive symptoms in COVID-19 patients with mild disease severity: clinical presentation, stool viral RNA testing, and outcomes Don't overlook digestive symptoms in patients with 2019 novel coronavirus disease (COVID-19) Early Epidemiological and Clinical Characteristics of 28 cases of coronavirus Disease in South Korea Effect of dexamethasone in hospitalized patients with COVID-19: preliminary report Effect of gastrointestinal symptoms on patients infected with COVID-19 Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) infection: a randomized clinical trial Effective treatment of severe COVID-19 patients with tocilizumab Eleven faces of coronavirus disease 2019 Emerging 2019 novel coronavirus (2019-NCoV) pneumonia Enteric involvement in hospitalised patients with COVID-19 outside Wuhan Epidemiologic and clinical characteristics of 26 cases of covid-19 arising from patient-to-patient transmission in Liaocheng, China Epidemiologic and Clinical characteristics of 91 hospitalized patients with COVID-19 in Zhejiang, China: a retrospective, multi-centre case series Epidemiologic and clinical characteristics of novel coronavirus infections involving 13 patients outside Wuhan, China Epidemiologic features and clinical course of patients infected with SARS-CoV-2 in Singapore Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study Epidemiological and clinical characteristics of 944 cases of 2019 novel coronavirus infection of non-COVID-19 Exporting City Epidemiological and clinical features of 125 hospitalized patients with COVID-19 in Epidemiological and initial clinical characteristics of patients with family aggregation of COVID-19 Epidemiological characteristics and clinical features of 32 critical and 67 noncritical cases of COVID-19 in Chengdu Epidemiological, clinical and virological characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms Epidemiological, clinical characteristics of cases of SARS-CoV-2 infection with abnormal imaging findings Epidemiological, clinical, and virological characteristics of 465 hospitalized cases of coronavirus disease 2019 (COVID-19) from Zhejiang province in China Evaluation of sars-cov-2 rna shedding in clinical specimens and clinical characteristics of 10 patients with COVID-19 in Macau Evidence for gastrointestinal infection of SARS-CoV-2 Experimental treatment with favipiravir for COVID-19: an open-label control study A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster Fecal specimen diagnosis 2019 novel coronavirus-infected pneumonia First cases of coronavirus disease 2019 (COVID-19) in the WHO European Region Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: a retrospective analysis of 1061 cases in Marseille, France Gastrointestinal and hepatic manifestations of 2019 novel coronavirus disease in a large cohort of infected patients from New York: clinical implications Gastrointestinal symptoms and COVID-19: case-control study from the United States Gastrointestinal symptoms of 95 cases with SARS-CoV-2 infection High prevalence of concurrent gastrointestinal manifestations in patients with SARS-CoV-2: early experience from California High-resolution chest CT features and clinical characteristics of patients infected with COVID-19 in Jiangsu, China Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial IL-6 signalling pathway inactivation with siltuximab in patients with COVID-19 respiratory failure: an observational cohort study Imaging and clinical features of patients with 2019 novel coronavirus SARS-CoV-2 Imaging features and evolution on CT in 100 COVID-19 pneumonia patients in Wuhan, China Investigation of three clusters of COVID-19 in Singapore: implications for surveillance and response measures Clinical course and outcomes of patients with severe acute respiratory syndrome coronavirus 2 infection: a preliminary report of the first 28 patients from the Korean Cohort Study on COVID-19 Clinical characteristics of SARS-CoV-2 infected pneumonia with diarrhea Multicenter analysis of clinical characteristics and outcomes in patients with COVID-19 who develop liver injury Observational study of hydroxychloroquine in hospitalized patients with Covid-19 Off-label use of tocilizumab for the treatment of SARS-CoV-2 pneumonia in Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study Patients with COVID-19 in 19 ICUs in Wuhan, China: a cross-sectional study Pilot prospective open, single-arm multicentre study on off-label use of tocilizumab in patients with severe COVID-19 Predictors of mortality for patients with COVID-19 pneumonia caused by SARSCoV-2: a prospective cohort study Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City Area Prevalence and characteristics of gastrointestinal symptoms in patients with SARS-CoV-2 infection in the United States: a multicenter cohort study Prolonged presence of SARS-CoV-2 viral RNA in faecal samples Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study Rapid asymptomatic transmission of COVID-19 during the incubation period demonstrating strong infectivity in a cluster of youngsters aged 16-23 years outside Wuhan and characteristics of young patients with COVID-19: a prospective contact-tracing study Relation between chest CT findings and clinical conditions of coronavirus disease (covid-19) pneumonia: a multicenter study Remdesivir for the treatment of Covid-19 -preliminary report Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial A report of clinical diagnosis and treatment of nine cases of coronavirus disease 2019 Retrospective analysis of clinical features in 101 death cases with COVID-19 Risk factors associated with acute respiratory distress syndrome and death in patients with Coronavirus disease 2019 pneumonia in Wuhan, China SARS-CoV-2 infection in 86 healthcare workers in two Dutch hospitals in SARS-CoV-2 viral load in upper respiratory specimens of infected patients Self-reported olfactory and taste disorders in SARS-CoV-2 patients: a cross-sectional study Sex-specific clinical characteristics and prognosis of coronavirus disease-19 infection in Wuhan, China: a retrospective study of 168 severe patients Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect , the company's public news and information Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information Smell and taste symptom-based predictive model for COVID-19 diagnosis Smell dysfunction: a biomarker for COVID-19 ST-segment elevation in patients with Covid-19 -a case series Time course of lung changes at chest CT during recovery from coronavirus disease 2019 (COVID-19) Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: a single center study of 100 patients in Typical radiological progression and clinical features of patients with coronavirus disease 2019 vier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information Virological assessment of hospitalized patients with COVID-2019 Sex differences in case fatality rate of COVID-19: insights from a multinational registry Mechanisms of sex disparities in influenza pathogenesis Sex differences in the response to influenza virus infection: modulation by stress Gender differences in patients with COVID-19: focus on severity and mortality Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis Obesity is a risk factor for severe COVID-19 infection: multiple potential mechanisms Is there a smoker's paradox in COVID-19? Cardiovascular risk factors. Insights from Framingham Heart Study People at High Risk For Flu Complications COVID-19 pandemic: cardiovascular complications and future implications Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Comorbid chronic diseases and acute organ injuries are strongly correlated with disease severity and mortality among COVID-19 patients: a systemic review and meta-analysis Olfactory dysfunction: a highly prevalent symptom of COVID-19 with public health significance Musculoskeletal symptoms in SARS-CoV-2 (COVID-19) patients The authors declare no conflict of interest.